| Feature | Details |
|---|---|
| Product Name | NUVALOP-ER 500 Tablets |
| Form | Extended-Release Tablets |
| Key Ingredients | Sodium Valproate 333 mg + Valproic Acid 145 mg |
| Total Strength | 500 mg (as extended-release formulation) |
| Core Benefits | Controls seizures, stabilizes mood, prevents migraines |
| Support Areas | Epilepsy, bipolar disorder, migraine prophylaxis |
| Recommended Usage | As prescribed by a neurologist or psychiatrist |
| Target Audience | Patients with epilepsy, mood disorders, or chronic migraine |
| Packaging Type | Blister pack |
| Available Pack Sizes | 10x1x10 tablets |
Composition: Divalproex Sodium Extended Release 500mg Packing: 10x10 Alu-Alu
Description : NUVALOP-ER 500 Tablets contain Sodium Valproate 333 mg and Valproic Acid 145 mg (total 500 mg), used for the effective management of epilepsy, bipolar disorder, and migraine prophylaxis. As an extended-release (ER) formulation, it ensures steady drug levels in the bloodstream, offering consistent seizure control and mood stabilization. NUVALOP-ER 500 is ideal for patients needing long-term therapy, reducing seizure frequency and intensity while improving quality of life. It is generally well-tolerated under proper medical supervision.
